The $1–5B bear book shed 9% of its shares short in six weeks, 5% of it in Oct alone, with 40 of 63 names cutting their positions. The names that covered lagged XBI less often than the rest, mainly in late Sep. When read name by name, the settlement dates say more about timing than the aggregate does.

At a glance

Covering Came Back Below $5B; Above It, Only in October

XBI $1–5B core and the tiers above it, Sep 15 → Oct 30, 2026 · core shares short fell from 1,399M to 1,277M while XBI rose +1.3%; above $5B the six-week rise came in late Sep and reversed in Oct

Shares short downShares short upLighter bar = October alone

Aggregate shares short by tier · six weeks (Sep 15 → Oct 30) and October alone (Sep 30 → Oct 30)

Aggregate change in shares short by tier, six weeks and October−10%−8%−6%−4%−2%0%+2%+4%$1–5B core63 names$1–5B core, six weeks: aggregate shares short −8.7%−8.7%$1–5B core, october: aggregate shares short −5.2%−5.2%$5–8B14 names$5–8B, six weeks: aggregate shares short +2.5%+2.5%$5–8B, october: aggregate shares short −2.6%−2.6%Above $8B32 namesAbove $8B, six weeks: aggregate shares short +2.6%+2.6%Above $8B, october: aggregate shares short −0.2%−0.2%

Share of core names that lagged XBI · Sep 15 → Oct 30

Share of names that lagged XBI: coverers vs the rest0%50%100%The 40 names that coveredThe 40 names that covered: 25 of 40 lagged XBI (62%)62% (25 of 40)The 23 that did notThe 23 that did not: 16 of 23 lagged XBI (70%)70% (16 of 23)

Aggregate = sum of shares short across each tier at the settlement dates. Covered = shares short down more than 2% over Sep 15 → Oct 30; lagged = stock return below XBI over the same dates.

Tiers by Sep 15 market cap. Source: FINRA bi-monthly settlements, Yahoo Finance.


Our last note left the $1–5B short book intact through a 10.5% XBI rally in August and a ~5% fall into mid-September. It did not hold through the next three settlements. Reported shares short fell at each of them, by 8.7% across the 63 names of the core from Sep 15 to Oct 30 and by 5.2% in Oct alone, and 40 names cut their positions by more than 2%.

The covering did not concentrate in the laggards. The names that covered lagged XBI less often than the rest of the core, by a wide margin in late Sep, and at similar rates in Oct. Xencor and CareDx say more about timing. Xencor's (XNCR) shorts cut a quarter of their position in the first half of Oct, before the ESMO data, and had rebuilt 5% by month-end. CareDx (CDNA) shorts added at every settlement, and the stock's 22% earnings rally came on Oct 30, after the trading cutoff for that settlement. The Nov 13 print is the first test of how much of the CareDx build survived the guidance raise, and of whether the Xencor rebuild continues.

Convention notes. We read four FINRA settlements: Sep 15, Sep 30, Oct 15 and Oct 30 (Oct 31 fell on a Saturday). Sep 15 → Oct 30 is the note window; the three half-months are the path. This note publishes about two weeks after the last settlement: where material events landed after Oct 30 (Q3 prints, a restructuring, buyback programs, a takeover tender), we flag them, but the flow cannot speak to them. Crowding is shares short as a share of shares outstanding (SI/SO). Icons beside names mark the event type: Clinical dataclinical data Regulatoryregulatory Financingfinancing Buyback or hedgebuyback or hedge Settlement datedated settlement.

Exhibit 1

Three Half-Months of Net Covering

XBI $1–5B core, n=63 · covers outnumbered builds whether XBI rose or fell; aggregate shares short down 8.7% in six weeks

Build: shares short up more than 2%Cover: shares short down more than 2%Flat: within ±2%
Sep 15 → Sep 30 · build: 22 names22BuildsSep 15 → Sep 30 · cover: 32 names32CoversSep 15 → Sep 30 · flat: 9 names9FlatSep 15 → Sep 30Shares short−3.7%XBI+2.4%Sep 30 → Oct 15 · build: 11 names11BuildsSep 30 → Oct 15 · cover: 30 names30CoversSep 30 → Oct 15 · flat: 22 names22FlatSep 30 → Oct 15Shares short−3.3%XBI−5.0%Oct 15 → Oct 30 · build: 22 names22BuildsOct 15 → Oct 30 · cover: 31 names31CoversOct 15 → Oct 30 · flat: 10 names10FlatOct 15 → Oct 30Shares short−1.9%XBI+4.1%

Count of the 63 core names by change in shares short between settlements; aggregate = sum of shares short across the 63. XBI = price return between the same settlement dates.

Core = XBI constituents with market cap of $1–5B on Sep 15, 2026 (Sep 15 close × shares outstanding), excluding PURR, TRAX, DMRA and COAG (corporate action or stale settlement). Members are the Nov 10 XBI holdings.

Source: FINRA bi-monthly settlements (Sep 15, Sep 30, Oct 15, Oct 30), Yahoo Finance.


1. What the Sep 30 settlement answered

The last note listed six tests for the Sep 30 settlement. All six now have an answer, and Oct adds a second reading for most.

Exhibit 2

Last Note’s Tests, Scored

Sep 30 watchlist by bucket, read at the Oct 30 settlement · shares short and price change Sep 15→Oct 30 · XBI $1–5B core and named names

BucketNamesWhat we said to watchShares short
Sep 15→Oct 30
Stock vs XBI
(pts)
Verdict at Oct 30
Book-level$1–5B coreA third window of builds outrunning covers would make persistence the base case for the fall calendar. If covering appears, whether into strength or weakness.Core−8.7%XBI+1.3% abs.Not metCovers outran builds in all three half-months; the names that covered lagged XBI less often than those that did not (62% against 70%).
Changed meaningXNCR, ARQTWhether shorts keep pressing XNCR into ESMO; whether the ARQT build continues now that the short has stopped paying.XNCR−18.1%
ARQT−1.6%
XNCR+24.3
ARQT+35.1
ResolvedBoth cut in October; neither left. XNCR cut 25% before the data and rebuilt 5%; ARQT’s October cover offset its September build.
Offside buildsVCEL, CDNA, RLAY, TYRAWhether shorts press or capitulate against relative strength; squeeze candidates if the positions keep failing.VCEL−2.2%
CDNA+14.1%
RLAY−1.9%
TYRA+0.3%
VCEL+0.1
CDNA+64.8
RLAY−4.5
TYRA−18.4
MixedThree barely moved (RLAY, TYRA flat; VCEL a small cover). CDNA is the clearest offside build: shares short rose 14% while the stock beat XBI by 36 points through Oct 29, the last trade date this settlement captures (65 with the post-print jump on Oct 30).
Dated catalystsERAS, SVRAWhether short interest builds into ERAS-0015 data (Nov 20) and the SVRA PDUFA (Nov 22), both after this settlement.ERAS+12.5%
SVRA−25.5%
ERAS−13.0
SVRA−9.6
PendingERAS built in every window; SVRA cut 34% in early October and rebuilt 12% into the PDUFA. Both resolve after Oct 30.
ResolutionVERA, RAREWhether covering continues after the thesis simplified (VERA) or paid (RARE).VERA−28.7%
RARE+42.6%
VERA−9.3
RARE+21.9
MixedVERA covered after its data. RARE did the opposite: the largest build in the core, after the FAYUVI approval.
MechanicalUTHRThe ASR borrow should start to unwind as Citi buys back through the fourth quarter.UTHR−34.4%UTHR+18.4Largely metConsistent with a partial unwind; the Oct 13 Liquidia settlement is a competing event, and the late-September step-up remains unexplained.

Shares short = FINRA settlements, Sep 15 and Oct 30, 2026. Stock vs XBI = close-to-close return Sep 15→Oct 30 less XBI (+1.3%); the core row shows XBI’s absolute return (grey). CDNA measured to Oct 29, the last trade date in the Oct 30 settlement: +36.4. Blue = a move of 20% or 20 points or more. Verdict tags: green = resolved or largely met, amber = mixed, rose = not met, outline = pending. ERAS and UTHR sit above the core on Sep 15 market cap ($5–8B and >$8B).

Source: FINRA short interest; Yahoo Finance prices.


Book-level. We asked whether a third consecutive window of builds would make persistence the base case. It did not happen: covers outran builds 32 to 22 in the second half of Sep, with XBI up 2.4%. Oct added two more covering windows.

Changed meaning: Xencor and Arcutis. Both cut in Oct; neither left the position.

Xencor (XNCR) shorts added another 3.9% into Sep 30, then cut 25% in the first half of Oct, with no company news in that window and before the XmAb819 abstract, scheduled to go live on Oct 18. The full ESMO data, released Oct 25, showed a 45.5% confirmed response rate in 11 evaluable patients at the proposed Ph3 dose, with a wide confidence interval (16.8% to 76.6%, 8-K). The stock beat XBI by 20 points in the second half of Oct and by 24 points over the window; shares short ended 18% lower, after a 5% rebuild in the window that contained both the abstract and the presentation. In Sep we wrote that the position had stopped fighting the tape and left the thesis to the data. The shorts did not wait for the data.

Arcutis (ARQT) was the valuation short that kept growing after the stock turned against it. Through Sep 30 that continued: shares short rose another 17.5% while the stock beat XBI by 10 points. Oct reversed it: shares short fell 5.5% and then 11.4%, while the stock beat XBI by 15 points and then 6, with no material company event in either window and no equity issuance (its $100 million at-the-market program reported no sales). Over the six weeks shares short ended roughly flat (−1.6%) and the stock beat XBI by 35 points. On Nov 4, after the settlement, Arcutis reported $143.9 million of Q3 ZORYVE net sales and raised full-year guidance. The position that kept growing in Sep was the one that cost the most.

Offside builds: Vericel, CareDx, Relay, Tyra. Three of the four barely moved: Relay (RLAY, −1.9%) and Tyra (TYRA, +0.3%) were flat on our ±2% band and lagged XBI (by 4.5 and 18.4 points), and Vericel (VCEL, −2.2%) was a small cover with the stock in line with XBI. None had a company event inside the windows; Vericel was also buying back stock in Sep (173,915 shares). CareDx (CDNA) is the exception, and the clearest offside position in the cohort: shares short rose 14.1%, with builds in every half-month, while the stock beat XBI by 36 points through Oct 29. After the close on Oct 29 CareDx reported Q3 revenue of $139 million, up 39%, and raised full-year guidance to $520–530 million, $30 million higher at the midpoint; about $15 million of the quarter's revenue was billed for earlier periods. Without it, revenue grew ~32% Y/Y, and the Q4 guide assumes ~$8 million of such revenue, so the long case now rests on recurring testing growth rather than collections. The Oct 30 settlement captures trades through Oct 29, so the build came before the print; the stock rose 22% on Oct 30, taking its six-week lead over XBI to 65 points, and the Nov 13 settlement is the first to show the response.

Settlement dateDated catalysts: Erasca and Savara. Erasca (ERAS), a $5–8B name, built in every window (+7.0%, +4.6%, +0.5%; +12.5% in total) while the stock lagged XBI by 13 points. On Nov 4 Erasca and Tango began a combination study of ERAS-0015 with vopimetostat; the EORTC-NCI-AACR data is Nov 20, after the next settlement. Savara (SVRA) took the opposite path: flat into Sep 30, a 34% cut in the first half of Oct, a 12% rebuild into the Nov 22 MOLBREEVI PDUFA. The stock lagged XBI by 10 points. Our view on that decision is in the Savara note; positioning into it is lighter than in Sep (SI/SO 21.1% to 14.6%), but rebuilding.

Resolution: Vera and Ultragenyx. Vera (VERA) covered after its data, not before. The final ORIGIN 3 topline came pre-market on Sep 15, after the trade cutoff for the Sep 15 settlement (Sep 14); shares short were flat into Sep 30 (+1.2%), then fell 21% and 11% in the two Oct windows, around the full presentation at Kidney Week on Oct 22, where the results met all prespecified endpoints. Crowding fell from 23.6% to 16.8%, and the stock still lagged XBI by 9 points. Vera also drew a $75 million term loan in late Oct. What remains is the commercial argument, held by a thinner crowd. Ultragenyx went the other way (section 4).

Buyback or hedgeMechanical: United Therapeutics. We expected the accelerated-share-repurchase (ASR) borrow to unwind as Citi bought back through the fourth quarter. The Sep ASR delivered 719,376 shares upfront, which matches the 0.74 million rise in shares short we flagged into Sep 15. Shares short then rose a further 0.8 million into Sep 30, to 3.6 million, which the ASR does not explain, before falling 32% and 25% in the two Oct windows, to 1.8 million, below both the 2.8 million at Sep 15 and the 2.1 million before the ASR began. The first Oct cut also coincides with the Oct 13 settlement with Liquidia, worth $320.4 million net to United Therapeutics over 2026–27. United Therapeutics confirmed on Oct 22 that the ASR was still running and added a new $2 billion authorization. The decline is consistent with a partial unwind of the dealer hedge, not proof of one; the late-Sep step-up remains unexplained.

2. The covering did not pick the laggards

Exhibit 1 shows the path by half-month. Shares short fell 3.7% in the second half of Sep while XBI rose 2.4%, 3.3% in the first half of Oct while it fell 5.0%, and 1.9% in the second half while it recovered 4.1%; over the six weeks XBI itself went almost nowhere ($154.03 on Sep 15, $155.98 on Oct 30). Seventeen names added and 6 barely moved, and median crowding slipped from 16.9% to 14.6%. The decline is broad rather than one deal. Recursion contributed 36.5 million shares of the 122 million net decline, with its Oct 15 offering one possible explanation; without it the core fell 7.0%. Taking out Novavax too, whose convertible invites hedging (section 5), leaves the six-week decline at 7.0% and Oct at 4.7%, but shrinks the late-Oct fall to 0.4%: covers still outnumbered builds that half-month, while most of the shares came from Recursion. Weighted by Sep 15 price instead of share count, which limits the pull of cheap stocks, the decline is 5.7%.

Each half-month had a different market. In none of them did the names that covered lag XBI more often than the names that did not.

Exhibit 3

Flow vs Price, Three Half-Months

XBI $1–5B core, n=63 · in no window did the names that covered lag XBI more often than the names that did not

Build: shares short up more than 2%Cover: shares short down more than 2%Flat: within ±2%

Sep 15 → Sep 30 · XBI +2.4%

50%of covers lagged XBI (16 of 32)
68%of the other names lagged (21 of 31)
-40-200+20+40-30-20-100+10+20+30+40+50Build, lagged · 13Build, beat · 9Cover, lagged · 16Cover, beat · 16Excess return vs XBI (pts)Δ shares short (%)NTLA · shares short −3.4% · +3.8 pts vs XBITNGX · shares short +6.3% · +2.1 pts vs XBISLS · shares short −6.7% · +6.7 pts vs XBINVAX · shares short −7.7% · +14.7 pts vs XBIREPL · shares short +1.6% · −0.8 pts vs XBIBEAM · shares short +6.4% · +2.9 pts vs XBIGLUE · shares short +2.2% · −10.5 pts vs XBIINBX · shares short +1.2% · −7.6 pts vs XBIRXRX · shares short −11.6% · +25.1 pts vs XBICELC · shares short −3.4% · −6.2 pts vs XBICRVS · shares short +3.6% · −13.4 pts vs XBISNDX · shares short −11.7% · +1.6 pts vs XBIABSI · shares short +0.5% · +33.3 pts vs XBINKTR · shares short +21.5% · −11.5 pts vs XBIRLAY · shares short +5.1% · −7.2 pts vs XBIVKTX · shares short +14.8% · +6.5 pts vs XBISRPT · shares short −10.4% · −14.4 pts vs XBIPVLA · shares short +8.5% · −11.2 pts vs XBIGRAL · shares short −6.5% · +82.3 pts vs XBINRIX · shares short −1.8% · −6.9 pts vs XBIANAB · shares short −3.7% · −10.5 pts vs XBIVERA · shares short +1.2% · −6.5 pts vs XBIZBIO · shares short +0.6% · −17.9 pts vs XBITSHA · shares short +7.0% · −6.1 pts vs XBISTOK · shares short +3.2% · −10.0 pts vs XBIJBIO · shares short +10.3% · −21.5 pts vs XBIIRON · shares short +0.9% · −5.1 pts vs XBIVRDN · shares short −7.7% · −8.0 pts vs XBIBCAX · shares short −4.5% · −20.3 pts vs XBISVRA · shares short +0.5% · −4.3 pts vs XBITYRA · shares short −4.7% · −16.4 pts vs XBIKURA · shares short −2.7% · −7.6 pts vs XBIIOVA · shares short −25.6% · +56.0 pts vs XBIIMNM · shares short +3.2% · −12.6 pts vs XBICDNA · shares short +4.6% · +21.1 pts vs XBIDYN · shares short +11.1% · −12.4 pts vs XBIKOD · shares short −12.1% · +185.0 pts vs XBICLDX · shares short +22.9% · −18.2 pts vs XBIPGEN · shares short +12.5% · +19.9 pts vs XBIVOR · shares short −1.1% · −16.9 pts vs XBICGEM · shares short −20.7% · −27.6 pts vs XBIQURE · shares short −12.1% · −46.3 pts vs XBIVCYT · shares short +21.1% · +12.3 pts vs XBIAVBP · shares short −3.6% · +5.9 pts vs XBIAGIO · shares short −7.2% · −1.0 pts vs XBIBCRX · shares short −21.1% · −0.3 pts vs XBIVCEL · shares short −5.1% · −1.3 pts vs XBIORIC · shares short −6.9% · +6.6 pts vs XBIBHVN · shares short −6.8% · +5.8 pts vs XBIVIR · shares short −23.8% · +4.7 pts vs XBIDNLI · shares short −9.8% · −0.9 pts vs XBIRCUS · shares short −5.1% · +3.8 pts vs XBIJANX · shares short −3.5% · +2.7 pts vs XBIMLYS · shares short −15.0% · −15.4 pts vs XBIIDYA · shares short −7.5% · −0.4 pts vs XBIAKTS · shares short +45.0% · −15.5 pts vs XBIMNKD · shares short −11.0% · +7.2 pts vs XBIADMA · shares short −14.9% · +14.1 pts vs XBIKLRA · shares short +45.6% · −17.5 pts vs XBIRARE · shares short +22.8% · +12.6 pts vs XBIXNCR · shares short +3.9% · +2.7 pts vs XBIARQT · shares short +17.5% · +10.1 pts vs XBIACAD · shares short −14.4% · −27.1 pts vs XBIRAREARQTACADXNCR

Sep 30 → Oct 15 · XBI −5.0%

60%of covers lagged XBI (18 of 30)
64%of the other names lagged (21 of 33)
-40-200+20+40-30-20-100+10+20+30+40+50Build, lagged · 5Build, beat · 6Cover, lagged · 18Cover, beat · 12Excess return vs XBI (pts)Δ shares short (%)NTLA · shares short −1.5% · −1.0 pts vs XBITNGX · shares short +0.6% · −4.0 pts vs XBISLS · shares short −2.5% · −2.9 pts vs XBINVAX · shares short +2.8% · +23.6 pts vs XBIREPL · shares short +0.2% · −6.2 pts vs XBIBEAM · shares short −4.7% · +6.2 pts vs XBIGLUE · shares short +4.9% · −10.2 pts vs XBIRARE · shares short −1.0% · +5.9 pts vs XBIINBX · shares short −0.5% · −4.6 pts vs XBIRXRX · shares short +2.5% · +5.7 pts vs XBICELC · shares short −6.6% · −19.2 pts vs XBICRVS · shares short +1.0% · −9.5 pts vs XBISNDX · shares short −1.3% · −22.4 pts vs XBIABSI · shares short −1.1% · −12.5 pts vs XBINKTR · shares short +0.4% · −32.7 pts vs XBIRLAY · shares short −5.8% · +0.9 pts vs XBIVKTX · shares short −1.5% · −11.0 pts vs XBISRPT · shares short −2.0% · +2.7 pts vs XBIPVLA · shares short −4.6% · −2.7 pts vs XBIGRAL · shares short +2.1% · +1.7 pts vs XBINRIX · shares short +16.7% · +10.2 pts vs XBIANAB · shares short +3.0% · +1.9 pts vs XBIZBIO · shares short +5.0% · −0.8 pts vs XBITSHA · shares short −6.9% · −18.4 pts vs XBISTOK · shares short −10.9% · −0.3 pts vs XBIJBIO · shares short −7.5% · +2.9 pts vs XBIIRON · shares short +2.6% · −8.4 pts vs XBIVRDN · shares short +0.2% · +0.0 pts vs XBIBCAX · shares short −3.7% · −0.3 pts vs XBITYRA · shares short +0.9% · −7.9 pts vs XBIKURA · shares short −0.7% · −4.4 pts vs XBIIOVA · shares short −9.1% · +4.3 pts vs XBIIMNM · shares short +3.1% · −14.1 pts vs XBICDNA · shares short +1.9% · +7.6 pts vs XBIDYN · shares short −2.0% · −0.1 pts vs XBIKOD · shares short −9.3% · −2.0 pts vs XBICLDX · shares short −12.8% · −5.7 pts vs XBIPGEN · shares short −2.4% · −10.9 pts vs XBIVOR · shares short −4.7% · +6.4 pts vs XBICGEM · shares short +0.1% · −3.8 pts vs XBIQURE · shares short +0.1% · −1.8 pts vs XBIVCYT · shares short −3.5% · +1.4 pts vs XBIAVBP · shares short −19.5% · −39.5 pts vs XBIAGIO · shares short −1.7% · +2.2 pts vs XBIBCRX · shares short −3.3% · +1.3 pts vs XBIVCEL · shares short +0.7% · +7.2 pts vs XBIORIC · shares short −5.5% · −0.2 pts vs XBIBHVN · shares short −6.1% · −9.4 pts vs XBIVIR · shares short +8.4% · −1.3 pts vs XBIDNLI · shares short +0.1% · −6.3 pts vs XBIRCUS · shares short −5.7% · −6.6 pts vs XBIJANX · shares short −6.3% · +5.2 pts vs XBIMLYS · shares short −4.7% · −8.9 pts vs XBIIDYA · shares short −1.1% · −6.9 pts vs XBIAKTS · shares short −8.5% · −12.8 pts vs XBIMNKD · shares short −2.6% · −13.2 pts vs XBIADMA · shares short −5.2% · +12.0 pts vs XBIKLRA · shares short −4.2% · +7.5 pts vs XBIACAD · shares short +9.9% · +2.8 pts vs XBIXNCR · shares short −25.1% · +1.2 pts vs XBIVERA · shares short −21.2% · −6.5 pts vs XBISVRA · shares short −34.0% · −3.1 pts vs XBIARQT · shares short −5.5% · +15.1 pts vs XBISVRAXNCRVERAARQT

Oct 15 → Oct 30 · XBI +4.1%

42%of covers lagged XBI (13 of 31)
44%of the other names lagged (14 of 32)
-40-200+20+40-30-20-100+10+20+30+40+50Build, lagged · 10Build, beat · 12Cover, lagged · 13Cover, beat · 18Excess return vs XBI (pts)Δ shares short (%)NTLA · shares short −0.2% · +5.8 pts vs XBINVAX · shares short −2.2% · −25.5 pts vs XBIREPL · shares short +6.2% · +45.7 pts vs XBIBEAM · shares short −0.6% · +6.0 pts vs XBIGLUE · shares short +0.9% · +2.2 pts vs XBIINBX · shares short −0.8% · −24.8 pts vs XBICELC · shares short +0.5% · +10.5 pts vs XBICRVS · shares short −1.2% · −2.3 pts vs XBISNDX · shares short +5.1% · −4.1 pts vs XBIABSI · shares short −3.2% · +21.2 pts vs XBINKTR · shares short −3.3% · −1.1 pts vs XBIRLAY · shares short −0.9% · +1.9 pts vs XBIVKTX · shares short −5.4% · −4.5 pts vs XBISRPT · shares short −13.6% · +0.5 pts vs XBIPVLA · shares short +8.1% · +10.6 pts vs XBIGRAL · shares short −2.2% · +1.7 pts vs XBINRIX · shares short −8.1% · +3.3 pts vs XBIXNCR · shares short +5.1% · +20.1 pts vs XBIANAB · shares short −6.3% · −5.0 pts vs XBIZBIO · shares short −9.4% · +7.6 pts vs XBITSHA · shares short +4.3% · +6.6 pts vs XBISTOK · shares short +4.5% · +2.7 pts vs XBIJBIO · shares short −7.5% · −2.0 pts vs XBIIRON · shares short −8.0% · +38.6 pts vs XBIVRDN · shares short −5.3% · +22.0 pts vs XBIBCAX · shares short −4.2% · −52.3 pts vs XBISVRA · shares short +12.3% · −2.5 pts vs XBITYRA · shares short +4.3% · +6.5 pts vs XBIARQT · shares short −11.4% · +6.1 pts vs XBIKURA · shares short −11.7% · +1.6 pts vs XBIIOVA · shares short +10.6% · −46.5 pts vs XBIIMNM · shares short −6.4% · +0.5 pts vs XBICDNA · shares short +7.0% · +27.0 pts vs XBIDYN · shares short −4.3% · +5.0 pts vs XBIKOD · shares short −4.5% · +8.4 pts vs XBICLDX · shares short +3.5% · −0.1 pts vs XBIPGEN · shares short −3.2% · −7.8 pts vs XBIVOR · shares short +0.8% · −2.4 pts vs XBICGEM · shares short +3.8% · +3.2 pts vs XBIQURE · shares short −2.5% · +6.1 pts vs XBIVCYT · shares short −2.7% · +8.5 pts vs XBIAVBP · shares short −14.8% · −15.6 pts vs XBIAGIO · shares short −5.4% · −9.6 pts vs XBIBCRX · shares short +3.9% · +1.5 pts vs XBIVCEL · shares short +2.4% · −6.0 pts vs XBIORIC · shares short −30.4% · −31.8 pts vs XBIVIR · shares short +3.9% · +3.8 pts vs XBIDNLI · shares short −5.0% · −0.9 pts vs XBIRCUS · shares short +6.6% · −24.4 pts vs XBIJANX · shares short +0.1% · −3.3 pts vs XBIMLYS · shares short +3.3% · −20.1 pts vs XBIIDYA · shares short −9.3% · −9.7 pts vs XBIAKTS · shares short +2.6% · −4.6 pts vs XBIMNKD · shares short +2.9% · +5.6 pts vs XBIADMA · shares short −7.6% · +2.2 pts vs XBIKLRA · shares short −1.8% · +5.7 pts vs XBIACAD · shares short −8.5% · +0.3 pts vs XBITNGX · shares short +7.7% · −4.1 pts vs XBISLS · shares short +6.3% · −18.8 pts vs XBIRARE · shares short +17.3% · +2.0 pts vs XBIRXRX · shares short −12.1% · −7.3 pts vs XBIVERA · shares short −10.6% · +4.3 pts vs XBIBHVN · shares short −16.1% · +30.8 pts vs XBIRAREBHVNRXRXVERATNGXSLS

Each dot is one core name; hover for values. Outlined, labelled names are the ones the note discusses for that window. Shaded band = ±2% change in shares short (flat).

Excess return = stock return less XBI return over the same settlement dates. Values beyond the axes are pinned to the edge.

Source: FINRA bi-monthly settlements, Yahoo Finance.


WindowXBICovers…of which lagged XBIOthers lagging XBI
Sep 15→30+2.4%3216 (50%)21 of 31 (68%)
Sep 30→Oct 15−5.0%3018 (60%)21 of 33 (64%)
Oct 15→30+4.1%3113 (42%)14 of 32 (44%)
Sep 30→Oct 30−1.1%3919 (49%)13 of 24 (54%)
Sep 15→Oct 30+1.3%4025 (62%)16 of 23 (70%)

In the selloff, most covers came in stocks that were lagging, which looks like profit-taking; in the rebound, most came in stocks that were beating XBI, which looks like a squeeze. Both are what the market would produce on its own: more stocks lagged in the first half of Oct and fewer in the second. In Oct the coverers and the rest lagged XBI at similar rates (49% against 54%), which says nothing about who moved first; measured to the last trade date each settlement captures, the two rates are identical (46%). Late Sep is the exception: 16 of 32 coverers lagged XBI against 21 of 31 other names, so that month's covering came in the stronger stocks. Builders lagged a little more often than the rest (12 of 17, 71%, against 29 of 46, 63%), a gap too small, on 17 names, to read as skill.

As in Sep, the size of the moves and the names behind them say more. Over the six weeks the median coverer lagged XBI by 9.4 points, the median builder by 6.2.

3. Covering around dated events

The aggregate shows no foresight. A few covers fall in a window that also contains a dated catalyst, and there the settlement dates narrow the order of events without fixing it.

  • RegulatoryBiohaven (BHVN). In the half-month to Sep 15 shorts built 7.6% into a partial clinical hold. Over the six weeks they fell 27%, with the largest cut (−16%) in the second half of Oct, when Biohaven disclosed that FDA had accepted its troriluzole resubmission in spinocerebellar ataxia (action goal in the first quarter of 2027, advisory committee planned). Earlier in Oct it licensed its IgG degrader portfolio to Ono for $80 million upfront. The stock beat XBI by 31 points in that half and 24 over the window. The cut and the acceptance fall in the same settlement window, and the stock rose 25% on Oct 22, so the data cannot say whether shorts left before the news or on it.

  • Clinical dataXencor (XNCR). The cover came first (first half of Oct, no news), the data second (Oct 25).

  • Clinical dataAcadia (ACAD). The reverse case: shares short fell 14% in the second half of Sep, when the stock lagged XBI by 27 points after the Ph2 RADIANT readout in Alzheimer's psychosis (Sep 24), where the 60 mg dose narrowly missed its primary endpoint (p≈0.06). That fits shorts taking profit on the miss.

Three commercial names covered with no clinical event in the window. Travere (TVTX) covered 26% over the window and Arcutis 11% in the second half of Oct, both with no material in-window news, ahead of Q3 prints that came after the settlement and beat: Travere's US FILSPARI net sales were $200.2 million on Nov 2, up 120%; Arcutis raised guidance on Nov 4. ADMA covered 25% while the stock beat XBI by 31 points, with no in-window event; it had been buying back stock in Jul and Aug.

Settlement data cannot show whether these were decisions about the catalyst or about the tape. The order of events is the most it allows.

Exhibit 4

Price Through the Settlements

Four names where the order of events matters · stock and XBI rebased to 100 on Sep 15; below each, the change in shares short in each half-month

StockXBIBuildCoverFlat (±2%)

BHVN · shares short fell in the FDA-acceptance window

8090100110120130140Sep 15Sep 30Oct 15Oct 30BHVN +25%XBI +1%FDA accepts resubmissionSep 15 · BHVN 12.34 (+0.0%) · XBI +0.0%Sep 16 · BHVN 12.02 (−2.6%) · XBI +0.1%Sep 17 · BHVN 13.89 (+12.6%) · XBI +2.7%Sep 18 · BHVN 13.62 (+10.4%) · XBI +1.7%Sep 21 · BHVN 14.22 (+15.2%) · XBI +2.7%Sep 22 · BHVN 14.85 (+20.3%) · XBI +5.1%Sep 23 · BHVN 13.67 (+10.8%) · XBI +0.8%Sep 24 · BHVN 13.19 (+6.9%) · XBI +1.3%Sep 25 · BHVN 12.99 (+5.3%) · XBI +0.6%Sep 28 · BHVN 13.27 (+7.5%) · XBI +1.7%Sep 29 · BHVN 13.29 (+7.7%) · XBI +1.8%Sep 30 · BHVN 13.35 (+8.2%) · XBI +2.4%Oct 01 · BHVN 13.14 (+6.5%) · XBI +0.3%Oct 02 · BHVN 12.87 (+4.3%) · XBI +0.3%Oct 05 · BHVN 12.97 (+5.1%) · XBI +1.4%Oct 06 · BHVN 12.08 (−2.1%) · XBI −2.0%Oct 07 · BHVN 11.88 (−3.7%) · XBI −2.5%Oct 08 · BHVN 11.93 (−3.3%) · XBI −3.1%Oct 09 · BHVN 12.08 (−2.1%) · XBI −0.2%Oct 12 · BHVN 11.81 (−4.3%) · XBI −1.7%Oct 13 · BHVN 11.42 (−7.5%) · XBI −4.7%Oct 14 · BHVN 10.93 (−11.4%) · XBI −4.7%Oct 15 · BHVN 11.43 (−7.4%) · XBI −2.8%Oct 16 · BHVN 10.78 (−12.6%) · XBI −6.3%Oct 19 · BHVN 11.35 (−8.0%) · XBI −4.0%Oct 20 · BHVN 11.81 (−4.3%) · XBI −0.5%Oct 21 · BHVN 11.75 (−4.8%) · XBI −0.8%Oct 22 · BHVN 14.69 (+19.0%) · XBI −1.6%Oct 23 · BHVN 13.88 (+12.5%) · XBI −2.9%Oct 26 · BHVN 14.45 (+17.1%) · XBI −2.3%Oct 27 · BHVN 15.29 (+23.9%) · XBI +0.5%Oct 28 · BHVN 15.52 (+25.8%) · XBI +2.3%Oct 29 · BHVN 16.49 (+33.6%) · XBI +2.4%Oct 30 · BHVN 15.42 (+25.0%) · XBI +1.3%Δ shares short by half-month · −27% over six weeksSep 15 → Sep 30 · shares short −6.8%−6.8%Sep 30 → Oct 15 · shares short −6.1%−6.1%Oct 15 → Oct 30 · shares short −16.1%−16.1%

XNCR · covered before the data

8090100110120130140Sep 15Sep 30Oct 15Oct 30XNCR +26%XBI +1%Data, Oct 25Sep 15 · XNCR 23.75 (+0.0%) · XBI +0.0%Sep 16 · XNCR 23.71 (−0.2%) · XBI +0.1%Sep 17 · XNCR 24.59 (+3.5%) · XBI +2.7%Sep 18 · XNCR 24.72 (+4.1%) · XBI +1.7%Sep 21 · XNCR 25.03 (+5.4%) · XBI +2.7%Sep 22 · XNCR 25.16 (+5.9%) · XBI +5.1%Sep 23 · XNCR 24.26 (+2.1%) · XBI +0.8%Sep 24 · XNCR 23.88 (+0.5%) · XBI +1.3%Sep 25 · XNCR 23.80 (+0.2%) · XBI +0.6%Sep 28 · XNCR 25.60 (+7.8%) · XBI +1.7%Sep 29 · XNCR 25.00 (+5.3%) · XBI +1.8%Sep 30 · XNCR 24.95 (+5.1%) · XBI +2.4%Oct 01 · XNCR 24.77 (+4.3%) · XBI +0.3%Oct 02 · XNCR 24.84 (+4.6%) · XBI +0.3%Oct 05 · XNCR 25.63 (+7.9%) · XBI +1.4%Oct 06 · XNCR 24.36 (+2.6%) · XBI −2.0%Oct 07 · XNCR 24.26 (+2.1%) · XBI −2.5%Oct 08 · XNCR 24.50 (+3.2%) · XBI −3.1%Oct 09 · XNCR 24.63 (+3.7%) · XBI −0.2%Oct 12 · XNCR 25.04 (+5.4%) · XBI −1.7%Oct 13 · XNCR 23.52 (−1.0%) · XBI −4.7%Oct 14 · XNCR 23.39 (−1.5%) · XBI −4.7%Oct 15 · XNCR 24.00 (+1.1%) · XBI −2.8%Oct 16 · XNCR 22.85 (−3.8%) · XBI −6.3%Oct 19 · XNCR 23.19 (−2.4%) · XBI −4.0%Oct 20 · XNCR 24.94 (+5.0%) · XBI −0.5%Oct 21 · XNCR 25.16 (+5.9%) · XBI −0.8%Oct 22 · XNCR 25.84 (+8.8%) · XBI −1.6%Oct 23 · XNCR 25.18 (+6.0%) · XBI −2.9%Oct 26 · XNCR 29.18 (+22.9%) · XBI −2.3%Oct 27 · XNCR 29.99 (+26.3%) · XBI +0.5%Oct 28 · XNCR 29.99 (+26.3%) · XBI +2.3%Oct 29 · XNCR 29.21 (+23.0%) · XBI +2.4%Oct 30 · XNCR 29.82 (+25.6%) · XBI +1.3%Δ shares short by half-month · −18% over six weeksSep 15 → Sep 30 · shares short +3.9%+3.9%Sep 30 → Oct 15 · shares short −25.1%−25.1%Oct 15 → Oct 30 · shares short +5.1%+5.1%

RARE · built while the stock rallied

8090100110120130140Sep 15Sep 30Oct 15Oct 30RARE +23%XBI +1%FAYUVI approvedSep 15 · RARE 13.07 (+0.0%) · XBI +0.0%Sep 16 · RARE 12.88 (−1.5%) · XBI +0.1%Sep 17 · RARE 14.50 (+10.9%) · XBI +2.7%Sep 18 · RARE 14.51 (+11.0%) · XBI +1.7%Sep 21 · RARE 14.65 (+12.1%) · XBI +2.7%Sep 22 · RARE 15.62 (+19.5%) · XBI +5.1%Sep 23 · RARE 14.88 (+13.8%) · XBI +0.8%Sep 24 · RARE 14.77 (+13.0%) · XBI +1.3%Sep 25 · RARE 14.50 (+10.9%) · XBI +0.6%Sep 28 · RARE 14.41 (+10.3%) · XBI +1.7%Sep 29 · RARE 15.32 (+17.2%) · XBI +1.8%Sep 30 · RARE 15.03 (+15.0%) · XBI +2.4%Oct 01 · RARE 14.75 (+12.9%) · XBI +0.3%Oct 02 · RARE 15.22 (+16.4%) · XBI +0.3%Oct 05 · RARE 14.50 (+10.9%) · XBI +1.4%Oct 06 · RARE 14.46 (+10.6%) · XBI −2.0%Oct 07 · RARE 14.89 (+13.9%) · XBI −2.5%Oct 08 · RARE 15.29 (+17.0%) · XBI −3.1%Oct 09 · RARE 15.48 (+18.4%) · XBI −0.2%Oct 12 · RARE 15.30 (+17.1%) · XBI −1.7%Oct 13 · RARE 14.92 (+14.2%) · XBI −4.7%Oct 14 · RARE 14.90 (+14.0%) · XBI −4.7%Oct 15 · RARE 15.17 (+16.1%) · XBI −2.8%Oct 16 · RARE 14.54 (+11.2%) · XBI −6.3%Oct 19 · RARE 15.07 (+15.3%) · XBI −4.0%Oct 20 · RARE 16.02 (+22.6%) · XBI −0.5%Oct 21 · RARE 15.92 (+21.8%) · XBI −0.8%Oct 22 · RARE 15.95 (+22.0%) · XBI −1.6%Oct 23 · RARE 15.65 (+19.7%) · XBI −2.9%Oct 26 · RARE 16.08 (+23.0%) · XBI −2.3%Oct 27 · RARE 16.75 (+28.2%) · XBI +0.5%Oct 28 · RARE 17.20 (+31.6%) · XBI +2.3%Oct 29 · RARE 16.78 (+28.4%) · XBI +2.4%Oct 30 · RARE 16.10 (+23.2%) · XBI +1.3%Δ shares short by half-month · +43% over six weeksSep 15 → Sep 30 · shares short +22.8%+22.8%Sep 30 → Oct 15 · shares short −1.0%−1.0%Oct 15 → Oct 30 · shares short +17.3%+17.3%

TNGX · pressed a working short

8090100110120130140Sep 15Sep 30Oct 15Oct 30TNGX −5%XBI +1%ESMO dataSep 15 · TNGX 23.89 (+0.0%) · XBI +0.0%Sep 16 · TNGX 23.35 (−2.3%) · XBI +0.1%Sep 17 · TNGX 23.49 (−1.7%) · XBI +2.7%Sep 18 · TNGX 21.75 (−9.0%) · XBI +1.7%Sep 21 · TNGX 22.33 (−6.5%) · XBI +2.7%Sep 22 · TNGX 25.53 (+6.9%) · XBI +5.1%Sep 23 · TNGX 24.45 (+2.3%) · XBI +0.8%Sep 24 · TNGX 24.63 (+3.1%) · XBI +1.3%Sep 25 · TNGX 24.92 (+4.3%) · XBI +0.6%Sep 28 · TNGX 24.30 (+1.7%) · XBI +1.7%Sep 29 · TNGX 24.42 (+2.2%) · XBI +1.8%Sep 30 · TNGX 24.95 (+4.4%) · XBI +2.4%Oct 01 · TNGX 24.45 (+2.3%) · XBI +0.3%Oct 02 · TNGX 23.24 (−2.7%) · XBI +0.3%Oct 05 · TNGX 23.08 (−3.4%) · XBI +1.4%Oct 06 · TNGX 21.90 (−8.3%) · XBI −2.0%Oct 07 · TNGX 21.83 (−8.6%) · XBI −2.5%Oct 08 · TNGX 22.57 (−5.5%) · XBI −3.1%Oct 09 · TNGX 23.81 (−0.3%) · XBI −0.2%Oct 12 · TNGX 24.17 (+1.2%) · XBI −1.7%Oct 13 · TNGX 22.22 (−7.0%) · XBI −4.7%Oct 14 · TNGX 22.19 (−7.1%) · XBI −4.7%Oct 15 · TNGX 22.70 (−5.0%) · XBI −2.8%Oct 16 · TNGX 22.04 (−7.7%) · XBI −6.3%Oct 19 · TNGX 23.53 (−1.5%) · XBI −4.0%Oct 20 · TNGX 25.25 (+5.7%) · XBI −0.5%Oct 21 · TNGX 26.98 (+12.9%) · XBI −0.8%Oct 22 · TNGX 27.93 (+16.9%) · XBI −1.6%Oct 23 · TNGX 23.34 (−2.3%) · XBI −2.9%Oct 26 · TNGX 22.20 (−7.1%) · XBI −2.3%Oct 27 · TNGX 22.89 (−4.2%) · XBI +0.5%Oct 28 · TNGX 22.23 (−6.9%) · XBI +2.3%Oct 29 · TNGX 22.53 (−5.7%) · XBI +2.4%Oct 30 · TNGX 22.72 (−4.9%) · XBI +1.3%Δ shares short by half-month · +15% over six weeksSep 15 → Sep 30 · shares short +6.3%+6.3%Sep 30 → Oct 15 · shares short +0.6%+0.6%Oct 15 → Oct 30 · shares short +7.7%+7.7%

Daily closes, Sep 15 → Oct 30, 2026; hover for values. Dashed lines = the Sep 30 and Oct 15 settlements. Markers = the dated events discussed in the text (Oct 25 fell on a Sunday). Bars capped at ±30%.

Source: Yahoo Finance (daily closes pulled Nov 12), FINRA bi-monthly settlements, company releases.


4. The shorts that pressed, and the ones that are offside

Seventeen core names added more than 2% over the window. Two kinds matter.

Pressing a working short. Tango (TNGX) built in every window (+6.3%, +0.6%, +7.7%; +15.2% in total) and is now the second most crowded name in the core at 28.5%. The second-half window includes Tango's ESMO data on Oct 23: an 82% response rate (18 of 22, 11 confirmed at cutoff) with vopimetostat plus daraxonrasib in MTAP-deleted pancreatic cancer, but grade 3 treatment-related adverse events in 40% of patients at the lower dose and dose-limiting toxicities in two of four at the higher one, which the company described as not well tolerated. The lower dose, chosen for Ph3, had no dose-limiting toxicities and no withdrawals for treatment-related events. The stock fell 16% that day. The settlement cannot place the build before or after the release, only inside the window that contained it. Tango sold nothing on its at-the-market program in Q3, which argues against a financing short. Nektar (NKTR, +18% in shares short, −43 points against XBI) and Celldex (CLDX, +11%, −23 points) are working builds on the same pattern: Nektar's shares short rose 21% before its Oct 1 data and then held flat while the stock fell 38% in the first half of Oct, and Celldex's rose 23% around its Sep 22 Ph3 readout, which the stock sold on safety.

SELLAS (SLS) answers part of the question we raised into this settlement, whether shorts would build into the REGAL trigger: they built in the window that contained it. Shares short fell 2.5% into Oct 15, then rose 6.3% into Oct 30, around the Oct 28 disclosure that the Ph3 REGAL trial had reached its 80th event, triggering the final analysis. The stock lagged XBI by 19 points in that half. On Nov 12 SELLAS guided topline to November. SLS sits at 28.3% SI/SO, third in the core. This is a position into a binary, not a view on a trend.

Offside and getting bigger. Ultragenyx (RARE) is the largest build in the core: shares short rose 42.6%, crowding from 16.8% to 23.2%, while the stock beat XBI by 22 points. The build came in two pushes. The first (+22.8%) came in the window that contained FDA's Sep 17 approval of FAYUVI (UX111), which came with a priority review voucher; Sep's Aspire failure had already paid the shorts. The second (+17.3%) came in the second half of Oct, after both voucher sales had been announced in the first half ($210 million on Oct 7 and $203 million on Oct 14: $413 million in gross sale prices and ~$350 million in expected combined net proceeds), a window in which shares short barely moved (−1.0%). The only company event we found in the second half is an Oct 19 patent settlement allowing a generic DOJOLVI from Jan 2033, which does not obviously explain a 17% build. On Nov 3, after the settlement, the company announced a restructuring with a roughly 20% workforce reduction and reported Q3 revenue of $173 million. The voucher proceeds and the cuts weaken a near-term financing short; what remains is whether recurring burn fits inside the runway through the launches.

CareDx (section 1) is the other large offside build. Replimune (REPL) added 8.2%, most of it (6.2%) in the second half, into a 46-point excess move after it reported early TUDRIQEV uptake on Oct 28 (first deliveries Oct 6; more than 15 prescribing institutions by Oct 23). The 45-day lock-up from its Aug offering ended Sep 24. That is consistent with shorts fading the launch in its first month. Veracyte (VCYT, +13.7% with the stock +23 points) sits in the same quadrant, with no company-specific event we could find in the window.

Kailera (KLRA) added 37% from a low 4.6% base, all of it in the first half of the window (+46% to Sep 30, with the stock down 15%). The 180-day lock-up from the Apr 16 IPO prospectus ran to Oct 13, and shares short fell 6% from Sep 30 to Oct 30, so the lock-up does not explain the build. It may have been positioning for the expiry; the settlements cannot tell.

5. Discount before counting

Four moves carry financing or hedging mechanics and should be discounted before they are read as views. Two sit in the core (Recursion, Novavax); Verastem was below $1B on Sep 15 and United Therapeutics above $8B.

FinancingVerastem (VSTM). Shares short rose 14.9% in the first half of Oct and 14.3% in the second. On Oct 14 Verastem priced a $250 million offering of 30.9 million shares at $8.00, the same day it reported initial VS-7375 data, and had sold another $28.8 million through its at-the-market program in Q3. The first-half build coincides with the deal; the second-half build is unexplained.

FinancingRecursion (RXRX). Shares short fell 20% over the window and crowding from 33.4% to 22.8%, while the stock beat XBI by 23 points. On Oct 15 Recursion priced a $200 million offering of 61.5 million shares at $3.25. The second-half cover (−12%) followed the deal; covering through an offering is common and says little about conviction.

Buyback or hedgeUnited Therapeutics (UTHR). The Oct "cover" is consistent with a partial ASR unwind (section 1), alongside the Liquidia settlement.

FinancingNovavax (NVAX). Its $225 million 4.625% convertible due 2031 (conversion price $11.14) remained outstanding at Sep 30, so part of the 28% SI/SO is likely arbitrage. Shares short fell 7% through a round trip in the stock (+24 points against XBI in the first half of Oct, −25 in the second), including the $125 million Sanofi milestone on Oct 29.

Equity offerings, convertible hedges and buyback dealers all add or remove short interest without changing anyone's view.

6. The crowded end covered with the rest

Ranked by crowding at the start of the window, the ten most crowded names covered in line with the rest: seven of the ten cut shares short by more than 2%, and the median moved −6.0% against −5.1% for the other 53. Recursion's offering (section 5) accounts for most of that difference; without it, the other nine cut a median 5.0%. The crowded names traded better than the rest (a median +0.9 points against XBI, against −9.6 for the other 53), but the covering was not concentrated among them.

Three names entered the Oct 30 top ten. Monte Rosa (GLUE, 24.4%) and Ultragenyx (23.2%) built their way in, and Inhibrx (INBX, 23.0%) held its position (−0.1%) through a 33-point underperformance after its ESMO head-and-neck presentation; Sarepta, Vera and Celcuity covered their way out. Intellia (NTLA, 31.6%) moved −5.0% in shares short and Beam (BEAM, 25.2%) +0.8%, before its Nov 10 BEACON data. Ranked at the end of the window, the ten most crowded moved a median +0.3%, which says where the exposure now sits, not how the crowded names traded.

Exhibit 5

Crowding Level and Six-Week Change

Top 20 of the core by Oct 30 SI/SO, where the exposure now sits · ranked on Sep 15 instead, the ten most crowded moved a median −6.0% in shares short, the other 53 −5.1%

Oct 30 levelSep 15 levelBuildCoverFlat (±2%)
Shares short ÷ shares outstanding (%)Δ shares shortStock vs XBI0102030Top 10 on Oct 30 · median Δ +0.3%Other 53 · median Δ −7.1%NTLA · SI/SO 31.6% (Sep 15 33.3%) · shares short −5.0% · +8.5 pts vs XBINTLA31.6−5.0%+8.5 ptsTNGX · SI/SO 28.5% (Sep 15 24.8%) · shares short +15.2% · −6.2 pts vs XBITNGX28.5+15.2%−6.2 ptsSLS · SI/SO 28.3% (Sep 15 29.2%) · shares short −3.3% · −15.5 pts vs XBISLS28.3−3.3%−15.5 ptsNVAX · SI/SO 28.1% (Sep 15 30.2%) · shares short −7.1% · +7.9 pts vs XBINVAX28.1−7.1%+7.9 ptsREPL · SI/SO 26.0% (Sep 15 24.2%) · shares short +8.2% · +33.9 pts vs XBIREPL26.0+8.2%+33.9 ptsBEAM · SI/SO 25.2% (Sep 15 25.1%) · shares short +0.8% · +16.0 pts vs XBIBEAM25.2+0.8%+16.0 ptsGLUE · SI/SO 24.4% (Sep 15 22.6%) · shares short +8.3% · −18.4 pts vs XBIGLUE24.4+8.3%−18.4 ptsRARE · SI/SO 23.2% (Sep 15 16.8%) · shares short +42.6% · +21.9 pts vs XBIRARE23.2+42.6%+21.9 ptsINBX · SI/SO 23.0% (Sep 15 23.1%) · shares short −0.1% · −33.3 pts vs XBIINBX23.0−0.1%−33.3 ptsRXRX · SI/SO 22.8% (Sep 15 33.4%) · shares short −20.4% · +23.1 pts vs XBIRXRX22.8−20.4%+23.1 ptsCELC · SI/SO 21.1% (Sep 15 23.2%) · shares short −9.3% · −17.7 pts vs XBICELC21.1−9.3%−17.7 ptsCRVS · SI/SO 21.1% (Sep 15 20.4%) · shares short +3.4% · −23.8 pts vs XBICRVS21.1+3.4%−23.8 ptsSNDX · SI/SO 21.0% (Sep 15 23.1%) · shares short −8.4% · −25.8 pts vs XBISNDX21.0−8.4%−25.8 ptsABSI · SI/SO 20.9% (Sep 15 21.7%) · shares short −3.8% · +38.9 pts vs XBIABSI20.9−3.8%+38.9 ptsNKTR · SI/SO 19.8% (Sep 15 16.8%) · shares short +18.0% · −42.9 pts vs XBINKTR19.8+18.0%−42.9 ptsRLAY · SI/SO 19.7% (Sep 15 20.3%) · shares short −1.9% · −4.5 pts vs XBIRLAY19.7−1.9%−4.5 ptsVKTX · SI/SO 18.9% (Sep 15 18.1%) · shares short +7.0% · −10.2 pts vs XBIVKTX18.9+7.0%−10.2 ptsSRPT · SI/SO 18.0% (Sep 15 24.1%) · shares short −24.1% · −11.4 pts vs XBISRPT18.0−24.1%−11.4 ptsPVLA · SI/SO 17.8% (Sep 15 16.1%) · shares short +11.9% · −4.6 pts vs XBIPVLA17.8+11.9%−4.6 ptsGRAL · SI/SO 17.8% (Sep 15 19.2%) · shares short −6.6% · +87.7 pts vs XBIGRAL17.8−6.6%+87.7 pts
Shares short ÷shares outstanding (%)Δ sharesshortvs XBI(pts)0102030Top 10 on Oct 30 · median Δ +0.3%Other 53 · median Δ −7.1%NTLA · SI/SO 31.6% (Sep 15 33.3%) · shares short −5.0% · +8.5 pts vs XBINTLA31.6−5.0%+8.5TNGX · SI/SO 28.5% (Sep 15 24.8%) · shares short +15.2% · −6.2 pts vs XBITNGX28.5+15.2%−6.2SLS · SI/SO 28.3% (Sep 15 29.2%) · shares short −3.3% · −15.5 pts vs XBISLS28.3−3.3%−15.5NVAX · SI/SO 28.1% (Sep 15 30.2%) · shares short −7.1% · +7.9 pts vs XBINVAX28.1−7.1%+7.9REPL · SI/SO 26.0% (Sep 15 24.2%) · shares short +8.2% · +33.9 pts vs XBIREPL26.0+8.2%+33.9BEAM · SI/SO 25.2% (Sep 15 25.1%) · shares short +0.8% · +16.0 pts vs XBIBEAM25.2+0.8%+16.0GLUE · SI/SO 24.4% (Sep 15 22.6%) · shares short +8.3% · −18.4 pts vs XBIGLUE24.4+8.3%−18.4RARE · SI/SO 23.2% (Sep 15 16.8%) · shares short +42.6% · +21.9 pts vs XBIRARE23.2+42.6%+21.9INBX · SI/SO 23.0% (Sep 15 23.1%) · shares short −0.1% · −33.3 pts vs XBIINBX23.0−0.1%−33.3RXRX · SI/SO 22.8% (Sep 15 33.4%) · shares short −20.4% · +23.1 pts vs XBIRXRX22.8−20.4%+23.1CELC · SI/SO 21.1% (Sep 15 23.2%) · shares short −9.3% · −17.7 pts vs XBICELC21.1−9.3%−17.7CRVS · SI/SO 21.1% (Sep 15 20.4%) · shares short +3.4% · −23.8 pts vs XBICRVS21.1+3.4%−23.8SNDX · SI/SO 21.0% (Sep 15 23.1%) · shares short −8.4% · −25.8 pts vs XBISNDX21.0−8.4%−25.8ABSI · SI/SO 20.9% (Sep 15 21.7%) · shares short −3.8% · +38.9 pts vs XBIABSI20.9−3.8%+38.9NKTR · SI/SO 19.8% (Sep 15 16.8%) · shares short +18.0% · −42.9 pts vs XBINKTR19.8+18.0%−42.9RLAY · SI/SO 19.7% (Sep 15 20.3%) · shares short −1.9% · −4.5 pts vs XBIRLAY19.7−1.9%−4.5VKTX · SI/SO 18.9% (Sep 15 18.1%) · shares short +7.0% · −10.2 pts vs XBIVKTX18.9+7.0%−10.2SRPT · SI/SO 18.0% (Sep 15 24.1%) · shares short −24.1% · −11.4 pts vs XBISRPT18.0−24.1%−11.4PVLA · SI/SO 17.8% (Sep 15 16.1%) · shares short +11.9% · −4.6 pts vs XBIPVLA17.8+11.9%−4.6GRAL · SI/SO 17.8% (Sep 15 19.2%) · shares short −6.6% · +87.7 pts vs XBIGRAL17.8−6.6%+87.7

Ranked by Oct 30 shares short ÷ shares outstanding within the 63-name core. Δ shares short and stock return over Sep 15 → Oct 30; stock vs XBI = excess return in percentage points.

Oct 30 level uses shares outstanding from the Nov pull; the Sep 15 marker uses the Sep-cycle pull. Source: FINRA bi-monthly settlements, Yahoo Finance.


7. Above $5B: late-Sep builds, Oct covers

Over six weeks the upper tiers moved the other way from the core; in Oct alone they covered too. Read them separately.

$5–8B. Fourteen names; shares short rose 2.5% in aggregate, all of it in late Sep (+5.2%), before falling 2.6% in Oct. All seven that added more than 2% lagged XBI (median −13.0 points): IMVT, RYTM, ERAS, SRRK, DNTH, MIRM and ALKS. Most of that is the tier, which lagged XBI by a median 10 points. Against the tier median, five of the seven still lagged, by a median of 3 points, and only Dianthus and Immunovant lagged by more than 10 (−12.3 and −11.3). Three of the seven were also issuing equity or carry convertible paper (MIRM's two convertible series; SRRK's and DNTH's at-the-market programs). The builders lag on both benchmarks, but by ~3 points against their tier, too little to read as a signal yet.

XBI above $8B. Thirty-two names, read against their own tier median (a +5.5% return across the window, about 4 points ahead of XBI), not against XBI. Shares short rose 2.6% in aggregate (+2.8% in late Sep, −0.2% in Oct). Twelve of 16 covers beat the tier median; 11 of 14 builds lagged it. Four of the tier's largest moves were financing events: Halozyme's $1.5 billion convertible (Sep 17–22), Vaxcyte's $1.15 billion equity-plus-convertible deal after OPUS-1 (Oct 5–9), Spyre's $378 million offering (Oct 5–13) and Arrowhead's $700 million convertible (ARWR, +25% in shares short). Alnylam (ALNY) is the clean read: shares short fell 29% in Oct, the first half with the stock moving with XBI and the second as it fell 34 points against it around a strong Q3 (product revenue $1.29 billion, +52%). BioMarin (BMRN) added 23% in Oct, the tier's largest build, with the stock roughly flat (−2.5%).

Exhibit 6

Upper Tiers: Late-Sep Builds, Oct Covers

Over six weeks shares short rose above $5B (2.5% at $5–8B, 2.6% above $8B) while the core fell 8.7%; in Oct alone all three tiers covered

Build: shares short up more than 2%Cover: shares short down more than 2%Flat: within ±2%Financing event

$5–8B · 14 names · aggregate +2.5% (Oct alone −2.6%)

5 of 7builds that lagged the tier median
4 of 6covers that beat it
-40-200+20+40-40-30-20-100+10+20+30+40Excess return vs tier median (pts)Δ shares short (%)SRRK · shares short +21.0% · −3.1 pts vs tier medianCRSP · shares short −9.9% · +8.3 pts vs tier medianRYTM · shares short +13.5% · +4.7 pts vs tier medianDNTH · shares short +5.1% · −12.3 pts vs tier medianIONS · shares short +1.3% · +1.2 pts vs tier medianALKS · shares short +29.6% · +7.6 pts vs tier medianERAS · shares short +12.5% · −2.6 pts vs tier medianCGON · shares short −18.1% · −1.8 pts vs tier medianCOGT · shares short −3.9% · +3.8 pts vs tier medianMIRM · shares short +3.9% · −0.4 pts vs tier medianTVTX · shares short −26.2% · −10.3 pts vs tier medianORKA · shares short −15.2% · +14.1 pts vs tier medianPTCT · shares short −20.1% · +0.4 pts vs tier medianIMVT · shares short +7.5% · −11.3 pts vs tier medianALKSTVTXSRRKPTCTCGONORKARYTMERASCRSPIMVTDNTHCOGTMIRMIONS

Above $8B · 32 names · aggregate +2.6% (Oct alone −0.2%)

11 of 14builds that lagged the tier median
12 of 16covers that beat it
-40-200+20+40-40-30-20-100+10+20+30+40Excess return vs tier median (pts)Δ shares short (%)TGTX · shares short −4.6% · +9.9 pts vs tier medianPRAX · shares short +10.9% · −14.1 pts vs tier medianCYTK · shares short +2.6% · −14.6 pts vs tier medianBBIO · shares short −3.3% · +4.1 pts vs tier medianEXEL · shares short −3.1% · +16.5 pts vs tier medianKRYS · shares short −3.8% · −6.8 pts vs tier medianSMMT · shares short +2.9% · −13.3 pts vs tier medianINCY · shares short +6.7% · −6.6 pts vs tier medianBIIB · shares short −6.3% · +11.9 pts vs tier medianAMGN · shares short −10.5% · +18.6 pts vs tier medianREGN · shares short −12.2% · +14.4 pts vs tier medianVRTX · shares short +2.0% · +3.1 pts vs tier medianPTGX · shares short +25.8% · −4.5 pts vs tier medianTWST · shares short −21.3% · +5.2 pts vs tier medianSYRE · shares short −4.2% · +0.7 pts vs tier medianHALO · shares short −9.9% · +17.7 pts vs tier medianIBRX · shares short +0.5% · −3.6 pts vs tier medianKYMR · shares short −20.2% · +6.4 pts vs tier medianPCVX · shares short −4.8% · −0.7 pts vs tier medianMDGL · shares short −5.2% · −23.2 pts vs tier medianMRNA · shares short +1.0% · +48.8 pts vs tier medianARWR · shares short +24.9% · −20.7 pts vs tier medianBMRN · shares short +40.2% · −14.7 pts vs tier medianINSM · shares short +30.3% · −11.6 pts vs tier medianROIV · shares short +25.8% · −12.0 pts vs tier medianRVMD · shares short +35.3% · −12.1 pts vs tier medianNBIX · shares short +18.9% · −8.1 pts vs tier medianUTHR · shares short −34.4% · +14.2 pts vs tier medianNTRA · shares short +26.6% · +12.6 pts vs tier medianALNY · shares short −24.0% · −36.2 pts vs tier medianGILD · shares short +16.2% · +11.2 pts vs tier medianABBV · shares short −18.9% · +6.6 pts vs tier medianBMRNRVMDUTHRINSMNTRAPTGXROIVARWRALNYTWSTKYMRABBVNBIXGILDHALOMDGLPCVXSYREMRNAIBRX

Each dot is one name; hover for values. Both tiers are read against their own tier median ($5–8B −9.1%, above $8B +5.5% over the window). Against XBI instead, 7 of 7 $5–8B builds lagged.

Values beyond the axes are pinned to the edge and labelled with the true excess. Shaded band = ±2% (flat).

Financing events: HALO and ARWR convertibles, PCVX and SYRE offerings, IBRX and SRRK and DNTH at-the-market or convertible paper. Tiers by Sep 15 market cap.

Source: FINRA bi-monthly settlements (Sep 15, Oct 30), Yahoo Finance, company filings.


8. Big pharma and the NBI's largest names

Scope, set in advance: read against each group's own median, not XBI; at 1–3% SI/SO a large percentage move is a change in sentiment, not crowding. For ADRs (NVO, NVS, AZN, GSK, SNY, and GMAB, ARGX, LKFT in the NBI), US short interest covers only the US line and is not compared across names.

Big pharma (Sep 30 → Oct 30). XLV rose 9.8% in Oct and the 15-name group a median 10.6%. Short interest is negligible everywhere (0.2–2.4% SI/SO). On US-listed lines, the moves were covers: Johnson & Johnson −23% (all in the first half of Oct), Pfizer −10.5%, Amgen −10.2%, Merck −5.9%. Eli Lilly's shares short barely moved (+2.5%) while the stock rose 22.5%, 12 points ahead of the group; Regeneron's rose 3.1% as the stock gained 22.4%. On ADR lines, Novo Nordisk (+21%), AstraZeneca (+16%) and Sanofi (+16%) added, and Novartis covered (−20%). Roche's US ADR line, missing from Yahoo, added 5.2% in FINRA's Oct 30 file. Events explain little of this. J&J reported on Oct 13 (sales beat, guidance raised, about $7 billion of charges for a proposed talc settlement and two deals), which fits the first-half cover. Novartis (Oct 27), GSK (Oct 28), Lilly, Merck and Bristol Myers (Oct 29) and AstraZeneca (Oct 30) reported in the final days before the Oct 30 settlement, so most of the change in shares short came before their results. Pfizer (Nov 3) and Novo Nordisk (Nov 4) reported after the window, and Pfizer had completed no share repurchases in 2026. Novartis bought back 18.8 million shares ($2.8 billion) under its $10 billion program in the nine months to Sep 30, and GSK finished its £2 billion buyback in Q2, so neither buyback is a window event.

NBI ≥$1B (60 names, excluding XBI members; Sep 30 → Oct 30, against ^NBI +2.9%). Shares short fell 5.5% in aggregate; median SI/SO 7.8% to 7.0%. The largest moves sort into four kinds, and only one is a view:

  • Takeovers. Pacira (PCRX) agreed on Oct 8 to be acquired by Viatris for $36.50 a share; shares short fell 59% and the stock beat ^NBI by 42 points. Silence (SLN) agreed on Oct 19 to a $20-per-ADS cash offer from Merck KGaA; the stock rose 78 points over ^NBI.
  • Arbitrage. Tempus (TEM, 13.8% SI/SO) carries $1.2 billion of convertibles and is paying for Personalis largely in its own stock (vote Nov 30); both invite hedging, which probably accounts for much of its short interest. Jazz (JAZZ) has exchangeable notes that became exchangeable in the fourth quarter, and Guardant (GH) two convertible series that became convertible Oct 1. Rapport (RAPP) added 30% in shares short in the second half of Oct, as it issued $172.5 million of convertibles after a Ph2 win in bipolar mania.
  • Issuer buybacks and listing effects. Lakefront (LKFT, formerly Galapagos) completed a €50 million buyback on Oct 16; shares short on its US line fell 61%. Grifols' (GRFS) +105% in late Sep is on its Class B ADS line only.
  • Views. Genmab (GMAB) reported three positive Ph3 readouts in Oct (EPCORE DLBCL-2 Oct 5, RAINFOL-02 Oct 23, LiGeR-HN1 Oct 28); the stock beat ^NBI by 57 points and shares short on the ADS line rose 59%, offside on its face, though at 1.6% SI/SO and on an ADR line. Omeros (OMER) added 12% after a negative CHMP opinion on narsoplimab (Oct 16), a working build. NewAmsterdam (NAMS, −37%) and UroGen (URGN, −34%) covered while their stocks lagged ^NBI by 20 and 22 points, which reads as profit-taking.
Exhibit 7

NBI and Big Pharma: What Moved and Why

Shares short Sep 30→Oct 30 · read against each group’s own benchmark · ADR lines are US lines only, never compared across names

Big pharma · 9 of 15 names · stock vs group median (group +10.6% in October; XLV +9.8%)
TickerSI/SO Oct 30Δ shares shortStock vs group
(pts)
Kind
LLY0.8%+2.5%+12.0Q3 Oct 29, guidance raised
JNJ0.7%−22.7%−7.4Q3 Oct 13, guidance raised; talc charge
MRK1.1%−5.9%−7.7Q3 Oct 29, guidance raised
PFE2.4%−10.5%−3.5No window event (Q3 Nov 3); no buyback in 2026
BMY2.3%+2.2%−10.4Q3 Oct 29, revenue guidance raised
NVS ADR0.2%−19.7%+2.2Q3 Oct 27, guidance raised; $10B buyback running
AZN ADR0.2%+15.8%+5.0Q3 Oct 30, guidance reaffirmed; ADR line
NVO ADR1.1%+21.1%−5.0No window result (Q3 Nov 4); CagriSema data Oct 20; ADR line
GSK ADR0.8%+9.1%−7.8Q3 Oct 28, guidance reaffirmed; ADR line
NBI ≥$1B, largest moves · 12 of 60 names ex-XBI · stock vs ^NBI (^NBI +2.9% in October)
TickerSI/SO Oct 30Δ shares shortStock vs ^NBI
(pts)
KindEvent
PCRX8.4%−58.5%+42.4TakeoverViatris, $36.50 a share, Oct 8
SLN3.9%−4.7%+77.8TakeoverMerck KGaA, $20 per ADS, Oct 19
TEM13.8%−2.3%−14.7Arbitrage$1.2B of convertibles; Personalis paid largely in stock
JAZZ9.0%+5.8%−9.6ArbitrageExchangeable notes exchangeable in Q4
GH7.0%−20.8%−2.6ArbitrageTwo convertible series convertible from Oct 1
RAPP6.7%+23.9%−28.3Arbitrage$172.5M convertible after Phase 2 win
LKFT ADR2.0%−60.8%+6.0Buyback / listingEUR 50M buyback completed Oct 16; ADR line
GRFS ADR2.3%−14.6%+7.9Buyback / listingClass B ADS line; +105% in shares short Sep 15→30
GMAB ADR1.6%+59.3%+57.1ViewThree positive Phase 3s in October; ADR line
OMER17.7%+12.7%−6.0ViewNegative CHMP opinion Oct 16
NAMS10.0%−36.9%−20.4ViewCovered while stock lagged ^NBI
URGN10.4%−34.2%−22.4ViewCovered while stock lagged ^NBI

Δ shares short = Sep 30→Oct 30 settlements (Yahoo, matched to FINRA on Sep 30); stock return Sep 30→Oct 30. Blue = move of 20% or more. Big pharma not shown (Δ shares short, stock vs group; no event review): ABBV −2.9% (+2.2 pts); AMGN −10.2% (+0.0 pts); REGN +3.1% (+11.8 pts); GILD −2.6% (+4.0 pts); SNY +15.8% (−3.0 pts); RHHBY +5.2% (+7.5 pts; FINRA Oct 30, ADR line).

Kind is a hypothesis consistent with dated public events, not something the flow demonstrates.

Source: Yahoo Finance, FINRA, company releases and SEC filings.


9. What the Nov settlements test

Exhibit 8

What the November Settlements Test

Watchlist by bucket, in order of information value · settlements of Nov 13 and Nov 30 · XBI $1–5B core and named names

BucketNamesKey dateWhat the next settlements tell us
Book-level$1–5B coreSettlement dateNov 13, Nov 30settlementsWhether the decline stays broad without the two financing-related core names, RXRX and NVAX (without them the core fell 7.0% over six weeks, 0.4% in late Oct), and whether the names that cover keep lagging XBI less often than the rest.
Binary positionsSLS, SVRARegulatoryNov 22SVRA PDUFAWhether SLS shorts hold into REGAL topline, which SELLAS now guides to November (Nov 12); if it lands by Nov 27, the Nov 30 settlement is the first post-data read. For SVRA, the Nov 13 settlement captures pre-PDUFA positions but publishes Nov 24, two days after the Nov 22 target; if FDA acts by the target date, Nov 30 (published Dec 9) is the first post-decision read.
Offside buildsCDNA, RARE, REPLNo dated eventWhether shorts press or capitulate: CDNA after its Oct 29 after-close print (the Oct 30 settlement predates the 22% move), RARE after the Nov 3 restructuring, REPL into its second launch month.
Working buildsTNGX, ERAS ($5–8B)Clinical dataNov 20ERAS-0015 dataERAS-0015 data at EORTC-NCI-AACR (Nov 20) after three windows of building. The Nov 13 settlement (published Nov 24) shows pre-data positions; Nov 30 (published Dec 9) is the first post-data read.
Post-catalystXNCR, BHVN, VERA, BEAMClinical dataNov 10BEAM data (past)Whether shorts return after the data (XNCR rebuilt 5% in the data window), BHVN’s advisory committee date, BEAM after BEACON (Nov 10).
MechanicalUTHR, VSTM, RXRX, PCRXTakeoverNov 16PCRX tender expiry (scheduled)UTHR’s ASR terminates in Q4; VSTM and RXRX show whether post-offering positions hold; PCRX’s tender is scheduled to expire Nov 16, subject to extension.

Settlement dates and FINRA publication: Nov 13 (published Nov 24) and Nov 30 (published Dec 9); positions on a settlement date reflect trades through the prior business day. Events from company releases and SEC filings.

Source: FINRA short interest; company filings.


Bottom line

For six weeks the $1–5B biotech short book did what it had not done all summer: it shrank, by ~9% of shares short, through a rising half-month, a falling one and a rising one.

The names that covered lagged XBI less often than those that did not (62% against 70%), mostly in late Sep, though the median coverer's stock still fell 8.2% over the window. The ten most crowded names on Sep 15 covered in line with the rest. The informative moves are narrower: shorts that left ahead of a dated event that went against them (Xencor) or in the same window as one (Biohaven), shorts that kept adding against a rising stock and are now offside (CareDx, ahead of its print; Ultragenyx; Replimune), and shorts that kept a working position through a release the market sold (Tango). Four of the largest moves came with offerings, a convertible or a buyback dealer's hedge. Above $5B, shares short rose over six weeks (2.5% at $5–8B, 2.6% above $8B) on late-Sep builds, then fell in Oct with the core, and in big pharma the moves were small and two-sided.

Method and limits

Crowding is shares short divided by shares outstanding (SI/SO), not free float, and we do not observe borrow cost or availability; flow is the change in shares short. We read four FINRA settlements (Sep 15, Sep 30, Oct 15, Oct 30). Sep 30 and Oct 30 shares short come from Yahoo and were checked against FINRA's own files: every available Yahoo value matched FINRA to the share, for all 154 live XBI names at Sep 30 and for 282 names across XBI, NBI and large pharma at Oct 30. Fourteen names had no Oct 30 Yahoo value; Roche's US ADR is taken from FINRA directly. Oct 15 is FINRA's file used directly. Flow uses a fixed ±2% band, set in advance. Hit rates compare the names that covered with the names that did not, over the same window, not with 50%. Crowding divides each date's shares short by the shares outstanding of that date's pull (the Sep-cycle pull for Sep 15, the Nov pull for Oct 30), which matters for issuers such as Recursion. Squeeze tests rank crowding at the start of the window; the Oct 30 ranking is used only to describe current exposure. Aggregates sum shares; a price-weighted version is given where it changes the reading. The cohort is the Nov 10 XBI holdings ranked by Sep 15 market cap (the Sep 15 close times shares outstanding from the Sep 15 pull), so names that left XBI before Nov 10 are not in it. The core is the $1–5B band, excluding PURR, TRAX and DMRA for corporate actions (n=63), and the upper tiers are cut the same way. The note keeps the original 63-name sample: COAG was left out because its Yahoo record was stale at Oct 15, and FINRA's files, which carry it, came in after the analysis; including it moves the six-week core decline from 8.7% to 8.6%. The NBI screen (≥$1B, excluding XBI members) uses the Nov 12 market cap, the one screen not set at Sep 15. Tiering by Sep 15 market cap avoids look-ahead in the size cut; membership, taken from the Nov 10 holdings, does not. It keeps Kodiak and GRAIL, which rallied out of the tier, and ten names that fell below $1B by November, most of them covers in falling stocks (ORIC, AVBP, CGEM, BCAX); on Nov 12 market cap the headline rates move by 1–3 points and the conclusion does not change. Excess return is each name against XBI on the same settlement dates; names above $8B are read against their tier median; NBI names against ^NBI; big pharma against its group median, with XLV shown. Days to cover, where cited, is Yahoo's roughly 30-day measure.

Settlement data cannot establish intra-window timing or motive, and positions on a settlement date reflect trades through the prior business day. Returns run between settlement-date closes; where a claim turns on positioning before an event (CareDx), we also quote the return to the last trade date the settlement captures. None of these returns was available to an investor acting on publication: the Oct 30 positions were published Nov 10. We treat a dated event as a likely driver only if it falls inside the measurement interval and plausibly changes valuation, financing risk, regulatory probability or positioning. Where we name a mechanism (ASR hedge, offering, convertible or merger arbitrage), it is a hypothesis consistent with dated public events, not something the flow demonstrates. Company events and capital-structure details come from company releases and SEC filings, and the events the argument rests on were checked against them.

Appendix A — Upper tiers detail

Tier $5–8B (14 names). Sorted by market cap on Sep 15. Change is Sep 15 → Oct 30; excess is against the tier median.

TickerCompanyMkt cap Sep 15 ($B)SI/SO Oct 30 (%)Shares short Δ (%)Stock (%)Excess (pts)
IONSIonis Pharmaceuticals7.912.7+1.3−7.9+1.2
ALKSAlkermes7.711.7+29.6−1.5+7.6
IMVTImmunovant7.69.0+7.5−20.4−11.3
RYTMRhythm Pharmaceuticals6.716.8+13.5−4.3+4.7
CGONCG Oncology6.410.3−18.1−10.8−1.8
ORKAOruka Therapeutics6.19.5−15.2+5.1+14.1
MIRMMirum Pharmaceuticals6.110.0+3.9−9.5−0.4
SRRKScholar Rock6.119.2+21.0−12.2−3.1
TVTXTravere Therapeutics5.910.0−26.2−19.4−10.3
DNTHDianthus Therapeutics5.916.5+5.1−21.4−12.3
ERASErasca5.710.6+12.5−11.7−2.6
COGTCogent Biosciences5.710.0−3.9−5.3+3.8
PTCTPTC Therapeutics5.59.3−20.1−8.7+0.4
CRSPCRISPR Therapeutics5.017.7−9.9−0.8+8.3

Tier above $8B (32 names). Sorted by market cap on Sep 15. Change is Sep 15 → Oct 30; excess is against the tier median.

TickerCompanyMkt cap Sep 15 ($B)SI/SO Oct 30 (%)Shares short Δ (%)Stock (%)Excess (pts)
ABBVAbbVie464.80.9−18.9+12.1+6.6
AMGNAmgen203.12.3−10.5+24.1+18.6
GILDGilead Sciences181.41.7+16.2+16.7+11.2
VRTXVertex Pharmaceuticals130.41.9+2.0+8.6+3.1
REGNRegeneron Pharmaceuticals78.32.2−12.2+19.9+14.4
MRNAModerna57.48.2+1.0+54.2+48.8
NTRANatera50.64.2+26.6+18.1+12.6
RVMDRevolution Medicines43.96.0+35.3−6.6−12.1
BIIBBiogen31.93.7−6.3+17.3+11.9
ALNYAlnylam Pharmaceuticals31.94.1−24.0−30.8−36.2
ROIVRoivant Sciences28.56.3+25.8−6.6−12.0
INSMInsmed26.26.4+30.3−6.1−11.6
INCYIncyte24.75.2+6.7−1.1−6.6
UTHRUnited Therapeutics21.54.3−34.4+19.7+14.2
NBIXNeurocrine Biosciences15.25.8+18.9−2.6−8.1
EXELExelixis14.110.5−3.1+22.0+16.5
SMMTSummit Therapeutics13.95.3+2.9−7.9−13.3
BBIOBridgeBio Pharma13.410.7−3.3+9.6+4.1
BMRNBioMarin Pharmaceutical12.57.3+40.2−9.2−14.7
MDGLMadrigal Pharmaceuticals12.19.2−5.2−17.8−23.2
HALOHalozyme Therapeutics12.112.0−9.9+23.2+17.7
ARWRArrowhead Pharmaceuticals10.08.2+24.9−15.2−20.7
KRYSKrystal Biotech10.010.3−3.8−1.3−6.8
CYTKCytokinetics9.612.9+2.6−9.1−14.6
KYMRKymera Therapeutics9.39.8−20.2+11.9+6.4
PTGXProtagonist Therapeutics9.315.7+25.8+1.0−4.5
TWSTTwist Bioscience9.214.8−21.3+10.6+5.2
PCVXVaxcyte8.89.7−4.8+4.8−0.7
PRAXPraxis Precision Medicines8.715.1+10.9−8.6−14.1
IBRXImmunityBio8.611.9+0.5+1.8−3.6
TGTXTG Therapeutics8.119.0−4.6+15.3+9.9
SYRESpyre Therapeutics8.012.2−4.2+6.2+0.7

Appendix B — Secondary attribution

Appendix B

Secondary Attribution: Flow Against Price

Ten core names with large moves not discussed in the main text · change in shares short and stock return in each half-month · the last column is the six-week stock return less XBI

Sep 15→30Sep 30→Oct 15Oct 15→30Sep 15→Oct 30
TickerShares shortStockShares shortStockShares shortStockStock vs XBI (pts)
Covered over the window
IOVA−25.6%+58.3%−9.1%−0.7%+10.6%−42.4%−10.7
QURE−12.1%−43.9%+0.1%−6.8%−2.5%+10.3%−43.7
MLYS−15.0%−13.1%−4.7%−13.9%+3.3%−16.0%−38.4
BCRX−21.1%+2.1%−3.3%−3.7%+3.9%+5.6%+2.5
IDYA−7.5%+2.0%−1.1%−11.9%−9.3%−5.6%−16.4
Built over the window
KLRA+45.6%−15.1%−4.2%+2.5%−1.8%+9.8%−5.7
NKTR+21.5%−9.1%+0.4%−37.7%−3.3%+3.0%−42.9
CLDX+22.9%−15.8%−12.8%−10.7%+3.5%+4.0%−23.1
VCYT+21.1%+14.7%−3.5%−3.6%−2.7%+12.7%+23.3
PVLA+8.5%−8.8%−4.6%−7.7%+8.1%+14.8%−4.6
Shares short behind the flow · millions of shares · crowding = shares short ÷ shares outstanding
TickerSep 15Sep 30Oct 30SI/SO Oct 30
IOVA87.1364.8365.1914.1%
QURE9.928.728.5112.1%
MLYS9.187.817.698.7%
BCRX34.8727.4927.6410.7%
IDYA9.939.188.248.5%
KLRA5.968.688.166.3%
NKTR5.746.976.7719.8%
CLDX8.9511.019.9412.7%
VCYT8.4010.189.5611.8%
PVLA2.332.522.6017.8%

Shading: green = stock beat (rose = lagged), deeper with size; capped at 50% (half-month) and 45 points (six weeks). Blue = a change in shares short of 20% or more, the rule used in every exhibit. XBI: +2.4%, −5.0%, +4.1% by half-month; +1.3% over six weeks.

Source: FINRA bi-monthly settlements (Sep 15, Sep 30, Oct 15, Oct 30), Yahoo Finance.


  • Clinical dataIovance (IOVA). Shares short fell 26% in the first window as the stock rose 58% after it raised 2026 revenue guidance to $410–420 million (from $350–370 million) on Sep 29, consistent with shorts covering into strength. Shares short rebuilt 11% in the second half while the stock fell 42%, which is mostly Oct 29, when it fell ~36% on updated lung-cancer data: a 24.6% response rate in 69 patients, in line with the 25.6% in 39 reported earlier, alongside a pivot to a retrospectively defined biomarker subgroup (59.1%; 13 of the 17 responses). The response rate held; what the market appears to have sold is the move to a post-hoc subgroup. The Oct 30 settlement reflects trades through Oct 29, so the data cannot say whether the rebuild came before or after the drop.

  • Clinical datauniQure (QURE). Shares short fell 12% in the first window as the stock fell 44%, including a one-day drop of about 37% on four-year data. That is a short covering into a collapse, not pressing it.

  • Mineralys (MLYS). The stock fell in every window (−13%, −14%, −16%); shares short fell 15% in the first and were flat after. We found no company event for the decline. The PDUFA date of Dec 22, 2026 comes from a secondary source we could not confirm.

  • BioCryst (BCRX). Shares short fell 21% in the first window with the stock flat (+2%) and were stable after. We did not tie the cover to an event.

  • IDEAYA (IDYA). Shares short fell 17% over the window as the stock lagged XBI by 16 points. A modest cover, with no event we could identify.

  • Kailera (KLRA). See section 4: the build (+46% to Sep 30) came before the lock-up expiry (Oct 13, 180 days from the Apr 16 prospectus) and shares short fell 6% over Oct.

  • Clinical dataNektar (NKTR). Shares short +21% before the Oct 1 data, flat after; the stock fell 38% in the first half of Oct, its worst day since Feb 2023. The price move favored the shorts, and shares short held.

  • Clinical dataCelldex (CLDX). Shares short +23% around the Sep 22 Ph3 readout (positive; stock −17% on safety); covered 13% in the second window.

  • Veracyte (VCYT). Shares short +21% in the first window as the stock rose 15%; no company event found.

  • RegulatoryPalvella (PVLA). Shares short +8% in each of the first and last windows. The stock rose 15% in the second half on Priority Review (announced Oct 28; PDUFA Feb 28, 2027).